Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026677 | 0.72 | HTT (0.42) | SMN1; SMN2 | |
| SCHEMBL20863049 | 0.71 | EPHX1 (0.33) | — | |
| SCHEMBL15338880 | 0.69 | POLB (0.44) | SMN1; SMN2 | |
| SCHEMBL30988285 | 0.69 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL21477756 | 0.68 | KDM4E (0.37) | SMN1; SMN2HSD17B10 | |
| SCHEMBL21516844 | 0.66 | ACACB (0.30) | — | |
| SCHEMBL19009022 | 0.65 | — | — | |
| SCHEMBL21172196 | 0.65 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10 | |
| SCHEMBL2719822 | 0.64 | EPHX1 (0.50) | SMN1; SMN2 | |
| SCHEMBL23893056 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH1C, ADH5, ADH1A | SMN1; SMN2 4864/4885HSD17B10 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.